Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $31.43 USD
Change Today +0.45 / 1.45%
Volume 165.0K
PODD On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 11:02 AM 06/30/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

600 Technology Park Drive

Suite 200

Billerica, MA 01821

United States

Phone: 978-600-7000

Fax: 978-600-0120

Insulet Corporation engages in the development, manufacturing and sale of proprietary OmniPod Insulin Management System (the ‘OmniPod System’), an insulin infusion system for people with insulin-dependent diabetes. The OmniPod System features a disposable tubeless OmniPod, which is worn on the body for approximately three days at a time and the company’s handheld, wireless personal diabetes manager (PDM). Conventional insulin pumps require people with insulin-dependent diabetes to learn to use, manage and wear various cumbersome components, including approximately 42 inches of tubing. The company owns Neighborhood Holdings, Inc. and its wholly-owned subsidiaries (collectively, ‘Neighborhood Diabetes’) to expand the company’s suite diabetes management product offerings and obtain access to various insulin dependent patients. Through Neighborhood Diabetes, the company provides customers with blood glucose testing supplies, traditional insulin pumps, pump supplies and pharmaceuticals; and has the ability to process claims as either durable medical equipment or through pharmacy benefits. The company sells the OmniPod System and other diabetes management supplies in the United States through direct sales to customers or through its distribution partners. The OmniPod system is available in multiple countries in Europe through its exclusive distribution partner, Ypsomed Distribution AG (Ypsomed), and in Canada. Under the Ypsomed distribution agreement, the company supplies OmniPods and PDMs to Ypsomed and it is responsible for the sale to the customer, including distribution, reimbursement and customer support. The OmniPod System The OmniPod System is primarily designed to provide people with insulin-dependent diabetes with a diabetes management solution, which provides lifestyle and other benefits and to expand the use of CSII (continuous subcutaneous insulin infusion) therapy. Discreet, Two-Part Design: Unlike conventional insulin pumps, the OmniPod System consists of just two discreet devices that communicate wirelessly, such as the OmniPod, a small disposable insulin infusion device worn beneath clothing that integrates an infusion set, automated cannula insertion, insulin reservoir, drive mechanism and batteries; and the PDM, a handheld device like a personal digital assistant that wirelessly programs the OmniPod with insulin delivery instructions, assists the patient with diabetes management and integrates a blood glucose meter. The OmniPod would operate approximately 72 hours (but no approximately 80 hours) after it is first activated. No Tubing: The OmniPod System’s proprietary design reduces the size of the insulin delivery mechanism, thereby eliminating the need for the external tubing required by conventional pumps. As a result of this design, the OmniPod could be worn discreetly beneath clothing and patients could move, dress, bathe, sleep and exercise without the encumbrance of the approximately 42 inches of tubing required by conventional insulin pumps. In addition to untethering people with insulin-dependent diabetes, the OmniPod System’s lack of tubing eliminates interruptions in insulin delivery resulting from kinking, leaking or disconnecting, which leads to the delivery of insulin. Pain-free Automated Cannula Insertion: The OmniPod is the CSII therapy device to feature an automated, hands-free cannula insertion system. This pain-free insertion system features the world’s fastest insertion and the smallest-gauge introducer needle available for insulin infusion systems. Cannula insertion is activated wirelessly using the PDM, so the patient never sees or handles an introducer needle, which promotes insertion, reduces patient anxiety, and increases the number of insertion sites available to patients. Easy To Train, Learn and Use: The company has designed the OmniPod System to fit within the normal daily routines of patients. The OmniPod System requires the fewest steps to start insulin delivery of all CSII therapies on the market by automating much of the process. In addition, the OmniPod System consists of just two devices, as opposed to approximately seven for conventional insulin pum

Page 12Next Page
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PODD:US $31.43 USD +0.45

PODD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.15 USD +0.14
DexCom Inc $79.68 USD +0.58
Smiths Group PLC 1,131 GBp +4.00
Takeda Pharmaceutical Co Ltd ¥5,911 JPY +75.00
Tandem Diabetes Care Inc $11.00 USD +0.15
View Industry Companies
 

Industry Analysis

PODD

Industry Average

Valuation PODD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 6.4x
Price/Book 22.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INSULET CORP, please visit www.insulet.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.